維立志博-B(09887)：LBL-024於奧帕替蘇米單抗黑色素瘤Ib/Ⅱ期試驗的首例患者成功用藥

智通財經

09/12

智通財經APP訊，維立志博-B(09887)發佈公告，評價奧帕替蘇米單抗(PD-L1/4-1BB雙特異性抗體LBL-024)單藥或聯合其他藥劑用於一線治療晚期黑色素瘤的Ib/Ⅱ期臨牀試驗(NCT07099430)首例患者已成功用藥。

本次開展的Ib/Ⅱ期、多中心臨牀試驗由福建省腫瘤醫院陳譽教授牽頭，全國多家醫院共同參與。該試驗旨在評價奧帕替蘇米單抗單藥或聯合用藥治療晚期黑色素瘤的療效及安全性。

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2566947599"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2566947599\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2566947599?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-09-12 12:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2566947599","market":"sh","top_or_hot":-1,"title":"維立志博-B(09887)：LBL-024於奧帕替蘇米單抗黑色素瘤Ib/Ⅱ期試驗的首例患者成功用藥","media":"智通財經","content":"<html><body><p>智通財經APP訊，<a href=\"https://laohu8.com/S/09887\">維立志博-B</a>(09887)發佈公告，評價奧帕替蘇米單抗(PD-L1/4-1BB雙特異性抗體LBL-024)單藥或聯合其他藥劑用於一線治療晚期黑色素瘤的Ib/Ⅱ期臨牀試驗(NCT07099430)首例患者已成功用藥。</p><p>本次開展的Ib/Ⅱ期、多中心臨牀試驗由福建省腫瘤醫院陳譽教授牽頭，全國多家醫院共同參與。該試驗旨在評價奧帕替蘇米單抗單藥或聯合用藥治療晚期黑色素瘤的療效及安全性。</p></body></html>","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>維立志博-B(09887)：LBL-024於奧帕替蘇米單抗黑色素瘤Ib/Ⅱ期試驗的首例患者成功用藥</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n維立志博-B(09887)：LBL-024於奧帕替蘇米單抗黑色素瘤Ib/Ⅱ期試驗的首例患者成功用藥\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">智通財經</strong><span class=\"h-time small\">2025-09-12 12:21</span>\n</p>\n</h4>\n</header>\n<article>\n<html><body><p>智通財經APP訊，<a href=\"https://laohu8.com/S/09887\">維立志博-B</a>(09887)發佈公告，評價奧帕替蘇米單抗(PD-L1/4-1BB雙特異性抗體LBL-024)單藥或聯合其他藥劑用於一線治療晚期黑色素瘤的Ib/Ⅱ期臨牀試驗(NCT07099430)首例患者已成功用藥。</p><p>本次開展的Ib/Ⅱ期、多中心臨牀試驗由福建省腫瘤醫院陳譽教授牽頭，全國多家醫院共同參與。該試驗旨在評價奧帕替蘇米單抗單藥或聯合用藥治療晚期黑色素瘤的療效及安全性。</p></body></html>\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"http://www.zhitongcaijing.com/content/detail/1344491.html\">智通財經</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1344491.html","article_id":"2566947599","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2566947599","pubTimestamp":1757650887,"columns":[{"name":"產品發布","id":31,"label_key":"productRelease"}],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通財經APP訊，維立志博-B(09887)發佈公告，評價奧帕替蘇米單抗(PD-L1/4-1BB雙特異性抗體LBL-024)單藥或聯合其他藥劑用於一線治療晚期黑色素瘤的Ib/Ⅱ期臨牀試驗(NCT07099430)首例患者已成功用藥。本次開展的Ib/Ⅱ期、多中心臨牀試驗由福建省腫瘤醫院陳譽教授牽頭，全國多家醫院共同參與。該試驗旨在評價奧帕替蘇米單抗單藥或聯合用藥治療晚期黑色素瘤的療效及安全性。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1161":"生物科技","09887":"维立志博-B"},"translate_title":"Verizhibo-B (09887): LBL-024 was successfully administered in the first patient of opatizumab melanoma phase Ib/II trial","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09887":1},"content_text":"智通財經APP訊，維立志博-B(09887)發佈公告，評價奧帕替蘇米單抗(PD-L1/4-1BB雙特異性抗體LBL-024)單藥或聯合其他藥劑用於一線治療晚期黑色素瘤的Ib/Ⅱ期臨牀試驗(NCT07099430)首例患者已成功用藥。本次開展的Ib/Ⅱ期、多中心臨牀試驗由福建省腫瘤醫院陳譽教授牽頭，全國多家醫院共同參與。該試驗旨在評價奧帕替蘇米單抗單藥或聯合用藥治療晚期黑色素瘤的療效及安全性。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}